Search > Results
You searched for: EV170006 (EV-TRACK ID)
Showing 1 - 8 of 8
Showing 1 - 8 of 8
Details | EV-TRACK ID | Experiment nr. | Species | Sample type | Separation protocol | First author | Year | EV-METRIC |
---|---|---|---|---|---|---|---|---|
EV170006 | 1/8 | Homo sapiens | Serum | (d)(U)C | Julich-Haertel H | 2017 | 37% | |
Study summaryFull title
All authors
Julich-Haertel H, Urban SK, Krawczyk M, Willms A, Jankowski K, Patkowski W, Kruk B, Krasnodębski M, Ligocka J, Schwab R, Richardsen I, Schaaf S, Klein A, Gehlert S, Sänger H, Casper M, Banales JM, Schuppan D, Milkiewicz P, Lammert F, Krawczyk M, Lukacs-Kornek V, Kornek M
Journal
J Hepatol
Abstract
BACKGROUND AND AIMS:
we previously reported that large extracellular vesicles, specifically AnnexinV (show more...)
EV-METRIC
37% (79th percentile of all experiments on the same sample type)
Reported
Not reported Not applicable EV-enriched
proteins
Protein analysis: analysis of three or more EV-enriched proteins
non
EV-enriched protein
Protein analysis: assessment of a non-EV-enriched protein
qualitative
and quantitative analysis
Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected.
electron
microscopy images
Particle analysis: inclusion of a widefield and close-up electron microscopy image
density
gradient
Separation method: density gradient, at least as validation of results attributed to EVs
EV density
Separation method: reporting of obtained EV density
ultracentrifugation specifics
Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps
antibody
specifics
Protein analysis: antibody clone/reference number and dilution
lysate
preparation
Protein analysis: lysis buffer composition
Study dataSample type
Serum
Sample origin
Control condition
Focus vesicles
microparticle
Separation protocol
Separation protocol
(d)(U)C
Adj. k-factor
284.4 (pelleting)
Protein markers
EV: CD147/ EpCAM/ ASGPR1/ ANXA5/ CD133
non-EV: None Proteomics
no
Show all info
Study aim
Biomarker
Sample
Species
Homo sapiens
Sample Type
Serum
Separation Method
(Differential) (ultra)centrifugation
dUC: centrifugation steps
Between 800 g and 10,000 g
Between 10,000 g and 50,000 g Pelleting performed
Yes
Pelleting: time(min)
60
Pelleting: rotor type
FA-45-24-11
Pelleting: speed (g)
20000
Pelleting: adjusted k-factor
284.4
Characterization: Protein analysis
Protein Concentration Method
Not determined
Flow cytometry
Type of Flow cytometry
MACSQuant® Analyzer 10
Calibration bead size
0.2,0.5
Antibody details provided?
No
Characterization: Lipid analysis
No
Extra information
We characterised various tumor-associated MPs (taMPs) in serum from various cancer patients aiming for the detection of liver cancer and differentiation from healthy subjects and other non-liver cancer entities. This led to several useful antigen combinations on taMPs that must be present simultaneously on the surface of the same MP in order to be accounted. That means, we reported several MP surface antigen combinations for the detection and differentiation of liver cancer (here: HCC and CCA).
|
||||||||
EV170006 | 2/8 | Homo sapiens | Serum | (d)(U)C | Julich-Haertel H | 2017 | 37% | |
Study summaryFull title
All authors
Julich-Haertel H, Urban SK, Krawczyk M, Willms A, Jankowski K, Patkowski W, Kruk B, Krasnodębski M, Ligocka J, Schwab R, Richardsen I, Schaaf S, Klein A, Gehlert S, Sänger H, Casper M, Banales JM, Schuppan D, Milkiewicz P, Lammert F, Krawczyk M, Lukacs-Kornek V, Kornek M
Journal
J Hepatol
Abstract
BACKGROUND AND AIMS:
we previously reported that large extracellular vesicles, specifically AnnexinV (show more...)
EV-METRIC
37% (79th percentile of all experiments on the same sample type)
Reported
Not reported Not applicable EV-enriched
proteins
Protein analysis: analysis of three or more EV-enriched proteins
non
EV-enriched protein
Protein analysis: assessment of a non-EV-enriched protein
qualitative
and quantitative analysis
Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected.
electron
microscopy images
Particle analysis: inclusion of a widefield and close-up electron microscopy image
density
gradient
Separation method: density gradient, at least as validation of results attributed to EVs
EV density
Separation method: reporting of obtained EV density
ultracentrifugation specifics
Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps
antibody
specifics
Protein analysis: antibody clone/reference number and dilution
lysate
preparation
Protein analysis: lysis buffer composition
Study dataSample type
Serum
Sample origin
Inguinal hernia
Focus vesicles
microparticle
Separation protocol
Separation protocol
(d)(U)C
Adj. k-factor
284.4 (pelleting)
Protein markers
EV: CD147/ EpCAM/ ASGPR1/ ANXA5/ CD133
non-EV: None Proteomics
no
Show all info
Study aim
Biomarker
Sample
Species
Homo sapiens
Sample Type
Serum
Separation Method
(Differential) (ultra)centrifugation
dUC: centrifugation steps
Between 800 g and 10,000 g
Between 10,000 g and 50,000 g Pelleting performed
Yes
Pelleting: time(min)
60
Pelleting: rotor type
FA-45-24-11
Pelleting: speed (g)
20000
Pelleting: adjusted k-factor
284.4
Characterization: Protein analysis
Protein Concentration Method
Not determined
Flow cytometry
Type of Flow cytometry
MACSQuant® Analyzer 10
Calibration bead size
0.2,0.5
Antibody details provided?
No
Characterization: Lipid analysis
No
Extra information
We characterised various tumor-associated MPs (taMPs) in serum from various cancer patients aiming for the detection of liver cancer and differentiation from healthy subjects and other non-liver cancer entities. This led to several useful antigen combinations on taMPs that must be present simultaneously on the surface of the same MP in order to be accounted. That means, we reported several MP surface antigen combinations for the detection and differentiation of liver cancer (here: HCC and CCA).
|
||||||||
EV170006 | 3/8 | Homo sapiens | Serum | (d)(U)C | Julich-Haertel H | 2017 | 37% | |
Study summaryFull title
All authors
Julich-Haertel H, Urban SK, Krawczyk M, Willms A, Jankowski K, Patkowski W, Kruk B, Krasnodębski M, Ligocka J, Schwab R, Richardsen I, Schaaf S, Klein A, Gehlert S, Sänger H, Casper M, Banales JM, Schuppan D, Milkiewicz P, Lammert F, Krawczyk M, Lukacs-Kornek V, Kornek M
Journal
J Hepatol
Abstract
BACKGROUND AND AIMS:
we previously reported that large extracellular vesicles, specifically AnnexinV (show more...)
EV-METRIC
37% (79th percentile of all experiments on the same sample type)
Reported
Not reported Not applicable EV-enriched
proteins
Protein analysis: analysis of three or more EV-enriched proteins
non
EV-enriched protein
Protein analysis: assessment of a non-EV-enriched protein
qualitative
and quantitative analysis
Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected.
electron
microscopy images
Particle analysis: inclusion of a widefield and close-up electron microscopy image
density
gradient
Separation method: density gradient, at least as validation of results attributed to EVs
EV density
Separation method: reporting of obtained EV density
ultracentrifugation specifics
Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps
antibody
specifics
Protein analysis: antibody clone/reference number and dilution
lysate
preparation
Protein analysis: lysis buffer composition
Study dataSample type
Serum
Sample origin
Colon carcinoma
Focus vesicles
microparticle
Separation protocol
Separation protocol
(d)(U)C
Adj. k-factor
284.4 (pelleting)
Protein markers
EV: CD147/ EpCAM/ ASGPR1/ ANXA5/ CD133
non-EV: None Proteomics
no
Show all info
Study aim
Biomarker
Sample
Species
Homo sapiens
Sample Type
Serum
Separation Method
(Differential) (ultra)centrifugation
dUC: centrifugation steps
Between 800 g and 10,000 g
Between 10,000 g and 50,000 g Pelleting performed
Yes
Pelleting: time(min)
60
Pelleting: rotor type
FA-45-24-11
Pelleting: speed (g)
20000
Pelleting: adjusted k-factor
284.4
Characterization: Protein analysis
Protein Concentration Method
Not determined
Flow cytometry
Type of Flow cytometry
MACSQuant® Analyzer 10
Calibration bead size
0.2,0.5
Antibody details provided?
No
Characterization: Lipid analysis
No
Extra information
We characterised various tumor-associated MPs (taMPs) in serum from various cancer patients aiming for the detection of liver cancer and differentiation from healthy subjects and other non-liver cancer entities. This led to several useful antigen combinations on taMPs that must be present simultaneously on the surface of the same MP in order to be accounted. That means, we reported several MP surface antigen combinations for the detection and differentiation of liver cancer (here: HCC and CCA).
|
||||||||
EV170006 | 4/8 | Homo sapiens | Serum | (d)(U)C | Julich-Haertel H | 2017 | 37% | |
Study summaryFull title
All authors
Julich-Haertel H, Urban SK, Krawczyk M, Willms A, Jankowski K, Patkowski W, Kruk B, Krasnodębski M, Ligocka J, Schwab R, Richardsen I, Schaaf S, Klein A, Gehlert S, Sänger H, Casper M, Banales JM, Schuppan D, Milkiewicz P, Lammert F, Krawczyk M, Lukacs-Kornek V, Kornek M
Journal
J Hepatol
Abstract
BACKGROUND AND AIMS:
we previously reported that large extracellular vesicles, specifically AnnexinV (show more...)
EV-METRIC
37% (79th percentile of all experiments on the same sample type)
Reported
Not reported Not applicable EV-enriched
proteins
Protein analysis: analysis of three or more EV-enriched proteins
non
EV-enriched protein
Protein analysis: assessment of a non-EV-enriched protein
qualitative
and quantitative analysis
Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected.
electron
microscopy images
Particle analysis: inclusion of a widefield and close-up electron microscopy image
density
gradient
Separation method: density gradient, at least as validation of results attributed to EVs
EV density
Separation method: reporting of obtained EV density
ultracentrifugation specifics
Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps
antibody
specifics
Protein analysis: antibody clone/reference number and dilution
lysate
preparation
Protein analysis: lysis buffer composition
Study dataSample type
Serum
Sample origin
Hepatocellular carcinoma
Focus vesicles
microparticle
Separation protocol
Separation protocol
(d)(U)C
Adj. k-factor
284.4 (pelleting)
Protein markers
EV: CD147/ EpCAM/ ASGPR1/ ANXA5/ CD133
non-EV: None Proteomics
no
Show all info
Study aim
Biomarker
Sample
Species
Homo sapiens
Sample Type
Serum
Separation Method
(Differential) (ultra)centrifugation
dUC: centrifugation steps
Between 800 g and 10,000 g
Between 10,000 g and 50,000 g Pelleting performed
Yes
Pelleting: time(min)
60
Pelleting: rotor type
FA-45-24-11
Pelleting: speed (g)
20000
Pelleting: adjusted k-factor
284.4
Characterization: Protein analysis
Protein Concentration Method
Not determined
Flow cytometry
Type of Flow cytometry
MACSQuant® Analyzer 10
Calibration bead size
0.2,0.5
Antibody details provided?
No
Characterization: Lipid analysis
No
Extra information
We characterised various tumor-associated MPs (taMPs) in serum from various cancer patients aiming for the detection of liver cancer and differentiation from healthy subjects and other non-liver cancer entities. This led to several useful antigen combinations on taMPs that must be present simultaneously on the surface of the same MP in order to be accounted. That means, we reported several MP surface antigen combinations for the detection and differentiation of liver cancer (here: HCC and CCA).
|
||||||||
EV170006 | 5/8 | Homo sapiens | Serum | (d)(U)C | Julich-Haertel H | 2017 | 37% | |
Study summaryFull title
All authors
Julich-Haertel H, Urban SK, Krawczyk M, Willms A, Jankowski K, Patkowski W, Kruk B, Krasnodębski M, Ligocka J, Schwab R, Richardsen I, Schaaf S, Klein A, Gehlert S, Sänger H, Casper M, Banales JM, Schuppan D, Milkiewicz P, Lammert F, Krawczyk M, Lukacs-Kornek V, Kornek M
Journal
J Hepatol
Abstract
BACKGROUND AND AIMS:
we previously reported that large extracellular vesicles, specifically AnnexinV (show more...)
EV-METRIC
37% (79th percentile of all experiments on the same sample type)
Reported
Not reported Not applicable EV-enriched
proteins
Protein analysis: analysis of three or more EV-enriched proteins
non
EV-enriched protein
Protein analysis: assessment of a non-EV-enriched protein
qualitative
and quantitative analysis
Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected.
electron
microscopy images
Particle analysis: inclusion of a widefield and close-up electron microscopy image
density
gradient
Separation method: density gradient, at least as validation of results attributed to EVs
EV density
Separation method: reporting of obtained EV density
ultracentrifugation specifics
Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps
antibody
specifics
Protein analysis: antibody clone/reference number and dilution
lysate
preparation
Protein analysis: lysis buffer composition
Study dataSample type
Serum
Sample origin
Liver tumour
Focus vesicles
microparticle
Separation protocol
Separation protocol
(d)(U)C
Adj. k-factor
284.4 (pelleting)
Protein markers
EV: CD147/ EpCAM/ ASGPR1/ ANXA5/ CD133
non-EV: None Proteomics
no
Show all info
Study aim
Biomarker
Sample
Species
Homo sapiens
Sample Type
Serum
Separation Method
(Differential) (ultra)centrifugation
dUC: centrifugation steps
Between 800 g and 10,000 g
Between 10,000 g and 50,000 g Pelleting performed
Yes
Pelleting: time(min)
60
Pelleting: rotor type
FA-45-24-11
Pelleting: speed (g)
20000
Pelleting: adjusted k-factor
284.4
Characterization: Protein analysis
Protein Concentration Method
Not determined
Flow cytometry
Type of Flow cytometry
MACSQuant® Analyzer 10
Calibration bead size
0.2,0.5
Antibody details provided?
No
Characterization: Lipid analysis
No
Extra information
We characterised various tumor-associated MPs (taMPs) in serum from various cancer patients aiming for the detection of liver cancer and differentiation from healthy subjects and other non-liver cancer entities. This led to several useful antigen combinations on taMPs that must be present simultaneously on the surface of the same MP in order to be accounted. That means, we reported several MP surface antigen combinations for the detection and differentiation of liver cancer (here: HCC and CCA).
|
||||||||
EV170006 | 6/8 | Homo sapiens | Serum | (d)(U)C | Julich-Haertel H | 2017 | 37% | |
Study summaryFull title
All authors
Julich-Haertel H, Urban SK, Krawczyk M, Willms A, Jankowski K, Patkowski W, Kruk B, Krasnodębski M, Ligocka J, Schwab R, Richardsen I, Schaaf S, Klein A, Gehlert S, Sänger H, Casper M, Banales JM, Schuppan D, Milkiewicz P, Lammert F, Krawczyk M, Lukacs-Kornek V, Kornek M
Journal
J Hepatol
Abstract
BACKGROUND AND AIMS:
we previously reported that large extracellular vesicles, specifically AnnexinV (show more...)
EV-METRIC
37% (79th percentile of all experiments on the same sample type)
Reported
Not reported Not applicable EV-enriched
proteins
Protein analysis: analysis of three or more EV-enriched proteins
non
EV-enriched protein
Protein analysis: assessment of a non-EV-enriched protein
qualitative
and quantitative analysis
Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected.
electron
microscopy images
Particle analysis: inclusion of a widefield and close-up electron microscopy image
density
gradient
Separation method: density gradient, at least as validation of results attributed to EVs
EV density
Separation method: reporting of obtained EV density
ultracentrifugation specifics
Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps
antibody
specifics
Protein analysis: antibody clone/reference number and dilution
lysate
preparation
Protein analysis: lysis buffer composition
Study dataSample type
Serum
Sample origin
Cirrhosis
Focus vesicles
microparticle
Separation protocol
Separation protocol
(d)(U)C
Adj. k-factor
284.4 (pelleting)
Protein markers
EV: CD147/ EpCAM/ ASGPR1/ ANXA5/ CD133
non-EV: None Proteomics
no
Show all info
Study aim
Biomarker
Sample
Species
Homo sapiens
Sample Type
Serum
Separation Method
(Differential) (ultra)centrifugation
dUC: centrifugation steps
Between 800 g and 10,000 g
Between 10,000 g and 50,000 g Pelleting performed
Yes
Pelleting: time(min)
60
Pelleting: rotor type
FA-45-24-11
Pelleting: speed (g)
20000
Pelleting: adjusted k-factor
284.4
Characterization: Protein analysis
Protein Concentration Method
Not determined
Flow cytometry
Type of Flow cytometry
MACSQuant® Analyzer 10
Calibration bead size
0.2,0.5
Antibody details provided?
No
Characterization: Lipid analysis
No
Extra information
We characterised various tumor-associated MPs (taMPs) in serum from various cancer patients aiming for the detection of liver cancer and differentiation from healthy subjects and other non-liver cancer entities. This led to several useful antigen combinations on taMPs that must be present simultaneously on the surface of the same MP in order to be accounted. That means, we reported several MP surface antigen combinations for the detection and differentiation of liver cancer (here: HCC and CCA).
|
||||||||
EV170006 | 7/8 | Homo sapiens | Serum | (d)(U)C | Julich-Haertel H | 2017 | 37% | |
Study summaryFull title
All authors
Julich-Haertel H, Urban SK, Krawczyk M, Willms A, Jankowski K, Patkowski W, Kruk B, Krasnodębski M, Ligocka J, Schwab R, Richardsen I, Schaaf S, Klein A, Gehlert S, Sänger H, Casper M, Banales JM, Schuppan D, Milkiewicz P, Lammert F, Krawczyk M, Lukacs-Kornek V, Kornek M
Journal
J Hepatol
Abstract
BACKGROUND AND AIMS:
we previously reported that large extracellular vesicles, specifically AnnexinV (show more...)
EV-METRIC
37% (79th percentile of all experiments on the same sample type)
Reported
Not reported Not applicable EV-enriched
proteins
Protein analysis: analysis of three or more EV-enriched proteins
non
EV-enriched protein
Protein analysis: assessment of a non-EV-enriched protein
qualitative
and quantitative analysis
Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected.
electron
microscopy images
Particle analysis: inclusion of a widefield and close-up electron microscopy image
density
gradient
Separation method: density gradient, at least as validation of results attributed to EVs
EV density
Separation method: reporting of obtained EV density
ultracentrifugation specifics
Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps
antibody
specifics
Protein analysis: antibody clone/reference number and dilution
lysate
preparation
Protein analysis: lysis buffer composition
Study dataSample type
Serum
Sample origin
Cholangiocarcinoma
Focus vesicles
microparticle
Separation protocol
Separation protocol
(d)(U)C
Adj. k-factor
284.4 (pelleting)
Protein markers
EV: ASGPR1/ EpCAM/ ANXA5/ CD133
non-EV: None Proteomics
no
Show all info
Study aim
Biomarker
Sample
Species
Homo sapiens
Sample Type
Serum
Separation Method
(Differential) (ultra)centrifugation
dUC: centrifugation steps
Between 800 g and 10,000 g
Between 10,000 g and 50,000 g Pelleting performed
Yes
Pelleting: time(min)
60
Pelleting: rotor type
FA-45-24-11
Pelleting: speed (g)
20000
Pelleting: adjusted k-factor
284.4
Characterization: Protein analysis
Protein Concentration Method
Not determined
Flow cytometry
Type of Flow cytometry
MACSQuant® Analyzer 10
Calibration bead size
0.2,0.5
Antibody details provided?
No
Characterization: Lipid analysis
No
Extra information
We characterised various tumor-associated MPs (taMPs) in serum from various cancer patients aiming for the detection of liver cancer and differentiation from healthy subjects and other non-liver cancer entities. This led to several useful antigen combinations on taMPs that must be present simultaneously on the surface of the same MP in order to be accounted. That means, we reported several MP surface antigen combinations for the detection and differentiation of liver cancer (here: HCC and CCA).
|
||||||||
EV170006 | 8/8 | Homo sapiens | Serum | (d)(U)C | Julich-Haertel H | 2017 | 37% | |
Study summaryFull title
All authors
Julich-Haertel H, Urban SK, Krawczyk M, Willms A, Jankowski K, Patkowski W, Kruk B, Krasnodębski M, Ligocka J, Schwab R, Richardsen I, Schaaf S, Klein A, Gehlert S, Sänger H, Casper M, Banales JM, Schuppan D, Milkiewicz P, Lammert F, Krawczyk M, Lukacs-Kornek V, Kornek M
Journal
J Hepatol
Abstract
BACKGROUND AND AIMS:
we previously reported that large extracellular vesicles, specifically AnnexinV (show more...)
EV-METRIC
37% (79th percentile of all experiments on the same sample type)
Reported
Not reported Not applicable EV-enriched
proteins
Protein analysis: analysis of three or more EV-enriched proteins
non
EV-enriched protein
Protein analysis: assessment of a non-EV-enriched protein
qualitative
and quantitative analysis
Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected.
electron
microscopy images
Particle analysis: inclusion of a widefield and close-up electron microscopy image
density
gradient
Separation method: density gradient, at least as validation of results attributed to EVs
EV density
Separation method: reporting of obtained EV density
ultracentrifugation specifics
Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps
antibody
specifics
Protein analysis: antibody clone/reference number and dilution
lysate
preparation
Protein analysis: lysis buffer composition
Study dataSample type
Serum
Sample origin
Non small cell lung carcinoma
Focus vesicles
microparticle
Separation protocol
Separation protocol
(d)(U)C
Adj. k-factor
284.4 (pelleting)
Protein markers
EV: ASGPR1/ EpCAM/ ANXA5/ CD133
non-EV: None Proteomics
no
Show all info
Study aim
Biomarker
Sample
Species
Homo sapiens
Sample Type
Serum
Separation Method
(Differential) (ultra)centrifugation
dUC: centrifugation steps
Between 800 g and 10,000 g
Between 10,000 g and 50,000 g Pelleting performed
Yes
Pelleting: time(min)
60
Pelleting: rotor type
FA-45-24-11
Pelleting: speed (g)
20000
Pelleting: adjusted k-factor
284.4
Characterization: Protein analysis
Protein Concentration Method
Not determined
Flow cytometry
Type of Flow cytometry
MACSQuant® Analyzer 10
Calibration bead size
0.2,0.5
Antibody details provided?
No
Characterization: Lipid analysis
No
Extra information
We characterised various tumor-associated MPs (taMPs) in serum from various cancer patients aiming for the detection of liver cancer and differentiation from healthy subjects and other non-liver cancer entities. This led to several useful antigen combinations on taMPs that must be present simultaneously on the surface of the same MP in order to be accounted. That means, we reported several MP surface antigen combinations for the detection and differentiation of liver cancer (here: HCC and CCA).
|
||||||||
1 - 8 of 8 |
EV-TRACK ID | EV170006 | |||||||
---|---|---|---|---|---|---|---|---|
species | Homo sapiens | |||||||
sample type | Serum | |||||||
condition | Control condition | Inguinal hernia | Colon carcinoma | Hepatocellular carcinoma | Liver tumour | Cirrhosis | Cholangiocarcinoma | Non small cell lung carcinoma |
separation protocol | (d)(U)C | (d)(U)C | (d)(U)C | (d)(U)C | (d)(U)C | (d)(U)C | (d)(U)C | (d)(U)C |
Exp. nr. | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 |
EV-METRIC % | 37 | 37 | 37 | 37 | 37 | 37 | 37 | 37 |